Maria Alejandra Fonseca-Mora

Maria Alejandra Fonseca-Mora

Auto-generated profile, based on publicly available information

Maria Alejandra Fonseca-Mora

Neuroscience Research Group (NEUROS). Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24 # 63C - 69, Bogotá, Colombia; Ophthalmology Interest Group, Neuroscience Research Group (NEUROS). Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario, Carrera 24 # 63C - 69, Bogotá, Colombia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
CGCarlos Humberto Cifuentes González
Carlos Humberto Cifuentes González
WRWilliam Rojas-Carabali
William Rojas-Carabali
MFMaria Alejandra Fonseca-Mora
Maria Alejandra Fonseca-Mora
GSGerman Mejia Salgado
German Mejia Salgado
JRJuliana Reyes-Guanes
Juliana Reyes-Guanes
ADAlejandra de-la-Torre
Alejandra de-la-Torre
This study aimed to estimate the prevalence of Herpes Zoster Ophthalmicus (HZO) and describe the sociodemographic disease distribution by age, sex, and region in Colombia using National Health Registry data between January 1, 2015, to December 31, 2019. We conducted a cross-sectional study using the Integrated Social Protection Information System database from the Colombian Ministry of Health, the unique official database in the country. We used the specific code of the International Classification of Diseases for HZO (B02.3) from 2015-2019 to estimate the prevalence and the demographic status of the disease in Colombia. The average prevalence was 0.99 in 100,000 inhabitants. Females represented 54.44% of the cases from 2,378 included patients. The distribution by age has a continual increase from the quinquennial group of 55 years. The geographic analysis shows a higher disease burden in the Andean region, followed by the Caribbean and Pacific regions. This is the first study that determines the HZO epidemiological characteristics based on a National Health database in our region. We found an age distribution similar to previous studies and suggest that higher altitudes correlate with a higher burden of the disease.

31 December 2021 in The Open Ophthalmology Journal
Verified
Journal Article
Open access
PDF file
MFMaría Alejandra Fonseca-Mora
María Alejandra Fonseca-Mora
PMPaula Tatiana Muñoz-Vargas
Paula Tatiana Muñoz-Vargas
JRJuliana Reyes-Guanes
Juliana Reyes-Guanes
WRWilliam Rojas-Carabali
William Rojas-Carabali
MCMiguel Cuevas
Miguel Cuevas
ADAlejandra de-la-Torre
Alejandra de-la-Torre
Purpose: The aim of the study was to report the first case of a patient with Terrien's Marginal Degeneration (TMD) who developed necrotizing anterior scleritis without systemic disease association, requiring systemic immunosuppressive treatment. Case Report: A 32-year-old female consulted for bilateral ocular burning and hyperemia. Initially, she was diagnosed with conjunctivitis and treated with topical antibiotics and corticosteroids, with mild transitory improvement but the progression of the disease. Years later, she attended the immunology consultation for a second opinion where TMD with ocular inflammatory component OU was diagnosed. Seven months later, she presented with severe pain, decreased visual acuity, and photophobia in OS. At the slit-lamp examination, necrotizing anterior scleritis with a high risk of perforation in OS was observed. The patient was referred to the rheumatologist and started treatment with systemic corticosteroids and cyclophosphamide, exhibiting a clinical improvement. The patient did not meet the criteria for any systemic illness associated with scleritis, such as autoimmune diseases or vasculitis. Thus, scleritis was related to the adjacent inflammatory process associated with TMD, as an atypical presentation of this disease. Conclusion: Although an inflammatory type of TMD has been proposed, it is essential to follow up closely these patients and consider necrotizing anterior scleritis, a severe ocular disease that requires prompt immunosuppressive management, as a possible atypical associated presentation of this disease.